Galmed Pharmaceuticals (GLMD) Operating Expenses (2013 - 2025)

Galmed Pharmaceuticals' Operating Expenses history runs 13 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 85.04% year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $8.5 million (up 35.55% YoY), while the FY2025 annual figure was $8.5 million, up 35.55% from the prior year.
• Operating Expenses was $3.0 million for Q4 2025 at Galmed Pharmaceuticals, up from $2.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $9.1 million in Q1 2021 to a low of -$250000.0 in Q1 2022.
• Historically, Operating Expenses has averaged $3.3 million across 5 years, with a median of $2.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 102.74% in 2022, then soared 900.8% in 2023.
• A 5-year view of Operating Expenses shows it stood at $7.5 million in 2021, then tumbled by 67.31% to $2.4 million in 2022, then dropped by 12.17% to $2.2 million in 2023, then declined by 23.57% to $1.6 million in 2024, then jumped by 85.04% to $3.0 million in 2025.
• The last three Operating Expenses figures came in at $3.0 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.